Next 10 |
VANCOUVER, British Columbia, and CAMBRIDGE, Mass., Oct. 08, 2019 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ: NVLN) (“Novelion” or the “Company”), announced that on October 7, 2019 the Nasdaq Office of General Counsel notified the Company that the Nasd...
VANCOUVER, British Columbia, and CAMBRIDGE, Mass., Oct. 03, 2019 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ: NVLN) (“Novelion” or the “Company”) today announced that it has filed its notice of meeting and definitive proxy statement with the applicable...
VANCOUVER, British Columbia and CAMBRIDGE, Mass., Sept. 25, 2019 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ: NVLN) (“Novelion” or the “Company”), announced that, further to its press release dated September 11, 2019, the acquisition by Amryt Pharma Pl...
This Week's Top Ideas Orion Engineered Carbons, which makes carbon black - a pigment and filler for rubber products - has pricing power and is set to generate a 27% levered free cash flow yield by fiscal 2021, says Jolyon Loo. - [[OEC]] - $994.1 million market cap. Floor covering maker ...
VANCOUVER, British Columbia, and CAMBRIDGE, Mass., Sept. 11, 2019 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ: NVLN) (“Novelion” or the “Company”), announced that, further to its press release dated August 30, 2019, the United States Bankruptcy Court f...
Editor's note: Seeking Alpha is proud to welcome Mark Taub as a new contributor. It's easy to become a Seeking Alpha contributor and earn money for your best investment ideas. Active contributors also get free access to SA Essential. Click here to find out more » I recommend buyin...
Novelion Therapeutics (NASDAQ: NVLN ) has received a notice from the Nasdaq Hearings Panel granting a 15-calendar day stay, until September 12, 2019, of the delisting of the Company’s common stock from the Nasdaq in response to its request for a hearing. More news on: Novelion The...
VANCOUVER, British Columbia and CAMBRIDGE, Mass., Aug. 30, 2019 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ: NVLN) (“Novelion” or the “Company”), announced that, further to its press release dated August 21, 2019, it has received a notice from the Nasd...
VANCOUVER, British Columbia and CAMBRIDGE, Mass., Aug. 21, 2019 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ: NVLN) (“Novelion” or the “Company”) announced that, further to its press release dated August 12, 2019, the British Columbia Securities Commiss...
Regeneron Pharmaceuticals (NASDAQ: REGN ) announces the successful outcome of a Phase 3 clinical trial, ELIPSE HoFH , evaluating evinacumab in patients with an inherited form of severely elevated levels of "bad" (LDL-C) cholesterol called homozygous familial hypercholesterolemia (HoFH). ...
News, Short Squeeze, Breakout and More Instantly...
Novelion Therapeutics Inc. Company Name:
NVLN Stock Symbol:
NASDAQ Market:
Novelion Therapeutics Inc. Website:
VANCOUVER, British Columbia, and CAMBRIDGE, Mass., Oct. 08, 2019 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ: NVLN) (“Novelion” or the “Company”), announced that on October 7, 2019 the Nasdaq Office of General Counsel notified the Company that the Nasd...
VANCOUVER, British Columbia, and CAMBRIDGE, Mass., Oct. 03, 2019 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ: NVLN) (“Novelion” or the “Company”) today announced that it has filed its notice of meeting and definitive proxy statement with the applicable...
VANCOUVER, British Columbia and CAMBRIDGE, Mass., Sept. 25, 2019 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ: NVLN) (“Novelion” or the “Company”), announced that, further to its press release dated September 11, 2019, the acquisition by Amryt Pharma Pl...